Nick Conley, PhD

Board of Directors

Co-founder & Chief Executive Officer

Nick Conley, PhD

Board of Directors

Co-founder & Chief Executive Officer

Dr. Conley is Chief Executive Officer, Co-founder, and a Director of EpiBiome. He completed a PhD in Chemistry and a postdoctoral fellowship in Developmental Biology at Stanford University, where he trained as a synthetic chemist and molecular biologist. Dr. Conley possesses a direct Nobel Laureate pedigree, having worked with Prof. W. E. Moerner at Stanford University, winner of the 2014 Nobel Prize in Chemistry. Dr. Conley was a Beckman Fellow, a National Science Foundation Graduate Research Fellow, a Lieberman Fellow, a Stanford Molecular Imaging Scholars Fellow, and a Younger Fellow. He has published 18 peer-reviewed journal articles on topics including palladium catalysis, super-resolution fluorescence imaging, single-molecule DNA detection, and cancer biology, and he holds four U.S. patents. Prior to founding EpiBiome, Dr. Conley was a Research Staff Member at HGST, a Western Digital Company.

Christina Tsai, PhD

Chief Scientific Officer
Co-founder & VP of Asian Business Development

Christina Tsai, PhD

Chief Scientific Officer
Co-founder & VP of Asian Business Development

Dr. Tsai is Chief Scientific Officer, Cofounder, and a Director of EpiBiome. After completing her undergraduate study in Chemistry at Tsing-Hua University in Taiwan, she received her PhD in Chemistry and Biochemistry from Texas A&M University. She did postdoctoral research in the Bioengineering Department at Stanford University where she engaged in several protein engineering projects, which included work on nerve-agent detoxifying enzymes and therapeutic protein development. In a spectacular feat of protein engineering, she increased the activity of an organophosphate-nerve-agent-degrading enzyme by more than 15,000-fold. Dr. Tsai has published six peer-reviewed journal articles and secured three U.S. patents. She brings her extensive expertise in biochemistry, microbiology, and molecular biology to advance EpiBiome’s technology innovation and product development.

Aeron Tynes Hammack, PhD

Board of Directors

Co-founder & Chief Operating Officer

Aeron Tynes Hammack, PhD

Board of Directors

Co-founder & Chief Operating Officer

Dr. Hammack is Chief Operations Officer, Cofounder, and a Director of EpiBiome. He received his bachelor’s degree in Electrical Engineering and Computer Science from The University of California at Berkeley, his PhD in Physics from UCSD, and was a postdoctoral fellow at LBNL. Dr. Hammack has more than 20 peer-reviewed publications in topics ranging from superfluidity, polymers, and surface chemistry to plasmonics and photonics. Before founding EpiBiome, he was a Research Staff Member at HGST where he developed nanoscale optical characterization techniques. In his current role at EpiBiome, he brings expertise in programming and data analysis, and oversees the bioinformatics program. Dr. Hammack is also an expert in microscopy and spectroscopy.

Lucia Mokres, DVM

Chief Medical Officer

Lucia Mokres, DVM

Chief Medical Officer

Dr. Mokres is Chief Medical Officer of EpiBiome. She leverages her clinical, research, and industry background to provide medical oversight and strategic direction for all clinical development activities, defines regulatory strategy, supports marketing and business development activities, and serves as the medical point of contact for external stakeholders.  She has held multiple roles within the human medical device industry, most recently lending her expertise to medical safety, clinical and regulatory affairs, research & development, quality affairs, and marketing functions at a Fortune 500 company. She received a BS in Physiology and Neuroscience at UC San Diego, graduated cum laude from the Colorado State University College of Veterinary Medicine and Biomedical Sciences, and completed her postdoctoral fellowship at Stanford University School of Medicine.

Bruno Marchon, PhD

Chief Technical Officer

Bruno Marchon, PhD

Chief Technical Officer

Dr. Marchon is Chief Technology Officer of EpiBiome. In his position, he is helping unravel predator-prey interactions in microbiological systems, and leveraging 3 billion years of evolution into developing the next generation of antimicrobial compounds. He has extensive experience in management of highly skilled R&D teams, with a strong focus on structure-property-performance relationships in technical materials and devices, and a first principle approach to problem solving. He started his career as a Staff Scientist for the French Research Council (CNRS), and was a visiting scientist at the Lawrence Berkeley National Laboratory. Dr. Marchon then joined the disk drive industry in Silicon Valley, working for Seagate, IBM, Hitachi and Western Digital in various senior R&D management positions. He has been directly involved in many game-changing implementations of technological breakthroughs in the area of disk drive reliability. He holds 60 US patents and has published over 110 peer-reviewed journal articles.

Tom Shyrock

Dr. Thomas Shryock

Scientific Advisory Board

Dr. Thomas Shryock

Scientific Advisory Board

Chief Scientific Officer / Managing Member
Antimicrobial Consultants, LLC, Greenfield, IN

Dr. Shryock founded Antimicrobial Consultants, LLC, in 2015 to partner with clients on the discovery, development and regulatory approval of antimicrobial agents, alternatives, antimicrobial resistance, microbiological issues, as well as on stewardship programs, policy development and training programs. He retired in 2015 as a Senior Research Advisor after 24 years of service for Elanco Animal Health, a Division of Eli Lilly & Co. He has also worked on expert panels for the World Health Organization, the World Organization for Animal Health, the Food and Agriculture Organization of the United Nations, Veterinary International Conference on Harmonization, and Codex to help set policies, guidelines, and recommendations on veterinary antibiotics. He is the recipient of the 2015 Clinical Laboratory Standards Institute Award for Excellence in Global Leadership in Standards Development.

Sylvain Moineau

Prof. Sylvain Moineau

Scientific Advisory Board

Prof. Sylvain Moineau

Scientific Advisory Board

Professor, Department of Biochemistry, Microbiology and Bioinformatics, Laval University, Quebec

Dr. Moineau’s research aims to understand the interactions between phages and bacteria, with direct applications in the dairy industry. His laboratory also houses the largest public collection of bacteriophages in the world (www.phage.ulaval.ca). Dr. Moineau received several awards among which the Food Specialty Award of the American Dairy Science Association, the 2013 NSERC Synergy Award for Innovation in partnership with Agropur.

Matt Sullivan

Prof. Matt Sullivan

Scientific Advisory Board

Prof. Matt Sullivan

Scientific Advisory Board

Co-founder of the Ecosystem Genomics Institute, University of Arizona
Assistant Professor, Departments of Microbiology, and Civil, Environmental and Geodetic Engineering, The Ohio State University Columbus, OH

As a Gordon and Betty Moore Foundation Investigator, Dr. Sullivan has helped lay the foundation for a modern, quantitative viral metagenomic sample-to-sequence pipeline and expanded our understanding of the global virosphere through illuminating viral dark matter.  He is a Kavli Frontiers in Science Fellow, and a Fulbright Fellow, and is a Beckman Foundation undergraduate and post-doctoral mentor.

Pamela Contag

Prof. Pamela Contag

Scientific Advisory Board

Prof. Pamela Contag

Scientific Advisory Board

Currently:
Founder and CEO, ConcentRx Inc.
Chairman and Trustee, Molecular Sciences Institute, Milpitas, CA
Director, Springboard Enterprises
Previously:
Founder and CEO, Xenogen
Founder and CEO, Cobalt

Scientist and entrepreneur, Dr. Pamela Contag founded four venture-backed start-up companies; Xenogen Corporation was listed as one of the ‘Top 25 Young Businesses’  by Fortune Small Business and received the R&D 100 award for achievements in Physics; Cobalt Technologies, was named multiple times as a Top 20 Company in Cleantech; Cygnet Biofuels, a company that consults and develops platforms in biomass and biofuels; and ConcentRx, a novel a cell-based immune therapy company for oncology indications. Pam was named one of the ‘Top 25 Women in Small Business’ by Fortune magazine. In 2011, Pam joined the Founding Board of the Startup America Partnership, an organization envisioned by the Case and Kauffman Foundation and The White House to identify, encourage and celebrate all entrepreneurs.

Brent Townshend

Dr. Brent Townshend

Scientific Advisory Board

Dr. Brent Townshend

Scientific Advisory Board

Department of Bioengineering, Stanford University, Stanford, CA
President, Townnshend Computer Tools, Menlo Park, CA
Artist, ModernBook Gallery, San Francisco, CA

Bioengineer, artist and inventor, Dr. Townshend invented and developed systems/devices primarily involved in data communications, cryptography, spam detection, speech recognition, language instruction, and biotech. He holds more than 100 patents. Over the years he started a sequence of successful high-tech companies, focused on signal processing — how to manipulate and process digital data to extract information or improve its visualization. He is currently a visiting researcher at Stanford University in the Bioengineering department.

Chris Lowe

Chris Lowe

Board of Directors

Chris Lowe

Board of Directors

Chris Lowe is currently a partner at FLG, a leading CFO consulting and board advisory firm. Most recently serving as interim CEO and CFO at Hansen Medical, Chris has over 15 years of senior management experience as CEO, CBO and CFO of various private and public life sciences, medical technology, and technology companies. Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees. Chris helps companies succeed by assisting them with corporate and financial strategy, including early stage financing, successive fundraising and IPOs, public company advising and Wall Street communications, licensing transactions, M&A, restructurings and coaching at every level of the C-Suite. In particular, he excels at helping companies navigate the challenges of accessing capital, M&A, licensing, restructurings and exits. During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies, and has overseen three SOX-404 implementations. Chris earned his B.S. from California Polytechnic State University, San Luis Obispo, and a MBA from St Mary’s University.